These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 29057723)

  • 1. Treatment effects of phosphodiesterase-5 inhibitors may improve with time following nerve-sparing radical prostatectomy.
    Fode M; Østergren PB; Jensen CFS; Jakobsen H; Sønksen J
    Scand J Urol; 2018 Apr; 52(2):108-110. PubMed ID: 29057723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of efficacy and satisfaction profile, between penile prosthesis implantation and oral PDE5 inhibitor tadalafil therapy, in men with nerve-sparing radical prostatectomy erectile dysfunction.
    Megas G; Papadopoulos G; Stathouros G; Moschonas D; Gkialas I; Ntoumas K
    BJU Int; 2013 Jul; 112(2):E169-76. PubMed ID: 23253640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of phosphodiesterase type 5 (PDE5) inhibitors in treating erectile dysfunction after bilateral nerve-sparing radical prostatectomy.
    Cui Y; Liu X; Shi L; Gao Z
    Andrologia; 2016 Feb; 48(1):20-8. PubMed ID: 25684196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of short- and long-term, regular and on-demand regimens of phosphodiesterase type 5 inhibitors in treating erectile dysfunction after nerve-sparing radical prostatectomy: a systematic review and meta-analysis.
    Tian D; Wang XY; Zong HT; Zhang Y
    Clin Interv Aging; 2017; 12():405-412. PubMed ID: 28260869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of erectile function after laparoscopic radical prostatectomy in a single center.
    Cathala N; Mombet A; Sanchez-Salas R; Rozet F; Barret E; Giuliano F; Galiano M; Prapotnich D; Kazzazi A; Djavan B; Jaffe J; Cathelineau X; Vallancien G
    Can J Urol; 2012 Aug; 19(4):6328-35. PubMed ID: 22892254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploratory Decision-Tree Modeling of Data from the Randomized REACTT Trial of Tadalafil Versus Placebo to Predict Recovery of Erectile Function After Bilateral Nerve-Sparing Radical Prostatectomy.
    Montorsi F; Oelke M; Henneges C; Brock G; Salonia A; d'Anzeo G; Rossi A; Mulhall JP; Büttner H
    Eur Urol; 2016 Sep; 70(3):529-37. PubMed ID: 26947602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of tadalafil treatment on erectile function recovery following bilateral nerve-sparing radical prostatectomy: a randomised placebo-controlled study (REACTT).
    Montorsi F; Brock G; Stolzenburg JU; Mulhall J; Moncada I; Patel HR; Chevallier D; Krajka K; Henneges C; Dickson R; Büttner H
    Eur Urol; 2014 Mar; 65(3):587-96. PubMed ID: 24169081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erectile function outcome after bilateral nerve sparing radical prostatectomy: which patients may be left untreated?
    Gallina A; Ferrari M; Suardi N; Capitanio U; Abdollah F; Tutolo M; Bianchi M; Saccà A; Salonia A; Rigatti P; Montorsi F; Briganti A
    J Sex Med; 2012 Mar; 9(3):903-8. PubMed ID: 22240189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Tadalafil Once-Daily or On-Demand vs Placebo on Return to Baseline Erectile Function After Bilateral Nerve-Sparing Radical Prostatectomy--Results from a Randomized Controlled Trial (REACTT).
    Mulhall JP; Brock G; Oelke M; Fode M; Probst KA; Henneges C; d'Anzeo G; Rossi A; Büttner H
    J Sex Med; 2016 Apr; 13(4):679-83. PubMed ID: 27045264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phosphodiesterase type 5 inhibitors in postprostatectomy erectile dysfunction: a critical analysis of the basic science rationale and clinical application.
    Hatzimouratidis K; Burnett AL; Hatzichristou D; McCullough AR; Montorsi F; Mulhall JP
    Eur Urol; 2009 Feb; 55(2):334-47. PubMed ID: 18986755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increasing the dose of vardenafil on a daily basis does not improve erectile function after unilateral nerve-sparing radical prostatectomy.
    Bannowsky A; van Ahlen H; Loch T
    J Sex Med; 2012 May; 9(5):1448-53. PubMed ID: 22462626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic review and meta-analysis of the use of phosphodiesterase type 5 inhibitors for treatment of erectile dysfunction following bilateral nerve-sparing radical prostatectomy.
    Wang X; Wang X; Liu T; He Q; Wang Y; Zhang X
    PLoS One; 2014; 9(3):e91327. PubMed ID: 24618671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Postoperative phosphodiesterase type 5 inhibitor administration increases the rate of urinary continence recovery after bilateral nerve-sparing radical prostatectomy.
    Gandaglia G; Albersen M; Suardi N; Gallina A; Abdollah F; Castiglione F; Capitanio U; Salonia A; Rigatti P; Hedlund P; Montorsi F; Briganti A
    Int J Urol; 2013 Apr; 20(4):413-9. PubMed ID: 22970988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of nightly versus on-demand vardenafil on recovery of erectile function in men following bilateral nerve-sparing radical prostatectomy.
    Montorsi F; Brock G; Lee J; Shapiro J; Van Poppel H; Graefen M; Stief C
    Eur Urol; 2008 Oct; 54(4):924-31. PubMed ID: 18640769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sexual Rehabilitation After Nerve-Sparing Radical Prostatectomy: Free-of-Charge Phosphodiesterase Type 5 Inhibitor Administration Improves Compliance to Treatment.
    Siena G; Mari A; Canale A; Mondaini N; Chindemi A; Greco I; Saleh O; Serni S; Nicita G; Minervini A; Carini M
    J Sex Med; 2018 Feb; 15(2):120-123. PubMed ID: 29425663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does topical hemostatic agent (Floseal
    Martorana E; Rocco B; Kaleci S; Pirola GM; Bevilacqua L; Bonetti LR; Puliatti S; Micali S; Bianchi G
    Int Urol Nephrol; 2017 Sep; 49(9):1519-1526. PubMed ID: 28677091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of Preoperative Atorvastatin Treatment On Erectile Function After Radical Prostatectomy: Results From a Subgroup of ESTO1, a Randomized, Double-Blind, Placebo-Controlled Study.
    Siltari A; Riikonen J; Fode M; Murtola TJ
    J Sex Med; 2019 Oct; 16(10):1597-1605. PubMed ID: 31405764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective comprehensive assessment of sexual function after retropubic non nerve sparing radical prostatectomy for localized prostate cancer.
    Trinchieri A; Nicola M; Masini F; Mangiarotti B
    Arch Ital Urol Androl; 2005 Dec; 77(4):219-23. PubMed ID: 16444937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Irbesartan promotes erection recovery after nerve-sparing radical retropubic prostatectomy: a retrospective long-term analysis.
    Segal RL; Bivalacqua TJ; Burnett AL
    BJU Int; 2012 Dec; 110(11):1782-6. PubMed ID: 23030689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preoperative erectile function is the only predictor of the use of a high number of phosphodiesterase type-5 inhibitors after bilateral nerve-sparing radical prostatectomy.
    Gandaglia G; Gallina A; Suardi N; Abdollah F; Passoni N; Bianchi M; Zaffuto E; Nini A; Vizziello D; Salonia A; Montorsi F; Briganti A
    Int J Impot Res; 2014; 26(6):201-4. PubMed ID: 24784890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.